Positions

Overview

  • Dr. Ochsenbauer pursued HIV research since her doctoral thesis at the German Cancer Research Center, Heidelberg. She came to UAB for postdoctoral training in molecular retrovirology with Dr. Eric Hunter. Over the last decade, she focused on questions pertinent to HIV-1 transmission She contributed several novel, highly relevant virologic reagents to the HIV prevention field, including the first infectious molecular clones that represent nucleotide exact copies of transmitted/founder (T/F) viruses, developed to link genetic analyses of T/F HIV-1 genomes with their biologic characteristics; and implementation of innovative, broadly applicable HIV-1/SIV reporter virus approaches to facilitate studies of HIV-1 transmission and prevention. In part through her work directing the Molecular Virology Core of the CAVD Comprehensive Antibody Vaccine Immunomonitoring Consortium, these technologies underpin development of next-generation HIV immunomonitoring assays, including neutralization, (primary) cell- and tissue explant-based virus inhibition (e.g. CD8 VIA, ADCC) assays, as well as various transmission-related research activities, including those of mucosal HIV-1 transmission in the female reproductive tract. Dr. Ochsenbauer also served as co-director of the UAB CFAR Virology Core. Her work is funded by CAVD, IAVI, and NIH (through R21, R01, CHAVI, P01 mechanisms).

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.  Cell Host and Microbe.  25:59-72.e8. 2019
    2018 Neutrophil extracellular traps prevent HIV infection in the female genital tract.  Mucosal Immunology.  11:1420-1428. 2018
    2018 Incomplete downregulation of CD4 expression affects HIV-1 Env conformation and antibody-dependent cellular cytotoxicity responses..  Journal of Virology.  92. 2018
    2017 Potent in vivo NK cellmediated elimination of HIV-1-infected cells mobilized by a gp120-bispecific and hexavalent broadly neutralizing fusion protein.  Journal of Virology.  91. 2017
    2017 Mass Cytometric Analysis of HIV Entry, Replication, and Remodeling in Tissue CD4+ T Cells.  Cell Reports.  20:984-998. 2017
    2017 Characterization of immune cells and infection by HIV in human ovarian tissues.  American Journal of Reproductive Immunology.  78. 2017
    2017 CD4 regulatory T cells augment HIV-1 expression of polarized M1 and M2 monocyte derived macrophages.  Virology.  504:79-87. 2017
    2017 Dendritic cells from the human female reproductive tract rapidly capture and respond to HIV.  Mucosal Immunology.  10:531-544. 2017
    2017 Mucosal stromal fibroblasts markedly enhance HIV infection of CD4+ T cells.  PLoS Pathogens.  13. 2017
    2017 The transcriptome of HIV-1 infected intestinal CD4+ T cells exposed to enteric bacteria.  PLoS Pathogens.  13. 2017
    2016 Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection.  EBioMedicine.  14:97-111. 2016
    2016 Superior efficacy of a human immunodeficiency virus vaccine combined with antiretroviral prevention in simian-human immunodeficiency virus-challenged nonhuman primates.  Journal of Virology.  90:5315-5328. 2016
    2016 Characterization of simian immunodeficiency virus variants anatomically compartmentalized in plasma and milk in chronically infected African green monkeys.  Journal of Virology.  90:8795-8808. 2016
    2016 High-throughput humanized mouse models for evaluation of HIV-1 therapeutics and pathogenesis.  Methods in Molecular Biology.  1354:221-235. 2016
    2015 Optimized Replicating Renilla Luciferase Reporter HIV-1 Utilizing Novel Internal Ribosome Entry Site Elements for Native Nef Expression and Function.  AIDS Research and Human Retroviruses.  31:1278-1296. 2015
    2015 Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.  Journal of Clinical Investigation.  125:4077-4090. 2015
    2015 Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy tanzanian adults.  PLoS ONE.  10. 2015
    2015 Association of HIV-1 envelope-specific breast milk IgA responses with reduced risk of postnatal mother-to-child transmission of HIV-1.  Journal of Virology.  89:9952-9961. 2015
    2015 In vivo activation of human NK cells by treatment with an interleukin-15 superagonist potently inhibits acute in vivo HIV-1 infection in humanized mice.  Journal of Virology.  89:6264-6274. 2015
    2015 The vaginal acquisition and dissemination of HIV-1 infection in a novel transgenic mouse model is facilitated by coinfection with herpes simplex virus 2 and is inhibited by microbicide treatment.  Journal of Virology.  89:9559-9570. 2015
    2014 Macrophage infection via selective capture of HIV-1-infected CD4 + T cells.  Cell Host and Microbe.  16:711-721. 2014
    2014 Global panel of HIV-1 env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.  Journal of Virology.  88:2489-2507. 2014
    2014 High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse.  Journal of Virology.  88:2025-2034. 2014
    2014 Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation.  Journal of Cell Biology.  206:867-876. 2014
    2014 Correction to Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation [Journal of Cell Biology, 206, 7, (2014), 867-876].  Journal of Cell Biology.  207:159. 2014
    2014 Deficient synthesis of class-switched, HIVneutralizing antibodies to the CD4 binding site and correction by electrophilic gp120 immunogen.  AIDS.  28:2201-2211. 2014
    2014 Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses.  Journal of Immunological Methods.  409:161-173. 2014
    2014 Innate Immunity in the Vagina (Part II): Anti-HIV Activity and Antiviral Content of Human Vaginal Secretions.  American Journal of Reproductive Immunology.  72:22-33. 2014
    2014 Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells.  Journal of Immunological Methods.  409:147-160. 2014
    2014 Synergy in monoclonal antibody neutralization of HIV-1 pseudoviruses and infectious molecular clones.  Journal of Translational Medicine.  12. 2014
    2013 Relative resistance of HIV-1 founder viruses to control by interferon-alpha.  Retrovirology.  10. 2013
    2013 Impact of HIV-1 backbone on neutralization sensitivity: Neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01-AE backbone.  PLoS ONE.  8. 2013
    2013 Detection of HIV-1 neutralizing antibodies in a human CD4 +/CXCR4+/CCR5+ T-lymphoblastoid cell assay system.  PLoS ONE.  8. 2013
    2013 Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1.  Proceedings of the National Academy of Sciences.  110:13540-13545. 2013
    2013 Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees.  Journal of Virology.  87:7828-7836. 2013
    2013 Mice Transgenic for CD4-Specific Human CD4, CCR5 and Cyclin T1 Expression: A New Model for Investigating HIV-1 Transmission and Treatment Efficacy.  PLoS ONE.  8. 2013
    2013 Phenotypic properties of transmitted founder HIV-1.  Proceedings of the National Academy of Sciences.  110:6626-6633. 2013
    2013 Estradiol Reduces Susceptibility of CD4+ T Cells and Macrophages to HIV-Infection.  PLoS ONE.  8. 2013
    2013 Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants.  Retrovirology.  10. 2013
    2013 Mucosal tissue tropism and dissemination of HIV-1 subtype B acute envelope-expressing chimeric virus.  Journal of Virology.  87:890-899. 2013
    2012 HIV-1 Expressing the Envelopes of Transmitted/Founder or Control/Reference Viruses Have Similar Infection Patterns of CD4 T-Cells in Human Cervical Tissue Ex Vivo.  PLoS ONE.  7. 2012
    2012 Antibody-dependent cellular cytotoxicity against primary hivinfected CD4 + T cells is directly associated with the magnitude of surface igg binding.  Journal of Virology.  86:8672-8680. 2012
    2012 Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.  Journal of Infectious Diseases.  206:431-441. 2012
    2012 Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication.  Journal of Virology.  86:6835-6846. 2012
    2012 Selective impact of HIV disease progression on the innate immune system in the human female reproductive tract.  PLoS ONE.  7. 2012
    2012 Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7.  PLoS Pathogens.  8. 2012
    2012 The role of natural killer (NK) cells and nk cell receptor polymorphisms in the assessment of HIV-1 neutralization.  PLoS ONE.  7. 2012
    2012 Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages.  Journal of Virology.  86:2715-2728. 2012
    2011 Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection.  Journal of Virology.  85:11196-11207. 2011
    2011 High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses.  Cytometry Part A.  79 A:603-612. 2011
    2011 An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum.  Journal of Virology.  85:7029-7036. 2011
    2011 Stromal down-regulation of macrophage CD4/CCR5 expression and NF-κB activation mediates HIV-1 non-permissiveness in intestinal macrophages.  PLoS Pathogens.  7. 2011
    2010 Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC.  Virology.  408:1-13. 2010
    2010 Uterine epithelial cell regulation of DC-SIGN expression inhibits transmitted/founder HIV-1 trans infection by immature dendritic cells.  PLoS ONE.  5. 2010
    2010 Anti-HIV activity in cervical-vaginal secretions from HIV-Positive and -Negative women correlate with innate antimicrobial levels and IgG antibodies.  PLoS ONE.  5. 2010
    2010 Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination.  Journal of Virology.  84:4998-5006. 2010
    2010 Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce β-chemokines.  Journal of Experimental Medicine.  207:763-776. 2010
    2010 GP41-specific antibody blocks cell-free HIV type 1 transcytosis through human rectal mucosa and model colonic epithelium.  Journal of Immunology.  184:3648-3655. 2010
    2010 Loss of DNAM-1 contributes to CD8+ T-cell exhaustion in chronic HIV-1 infection.  European Journal of Immunology.  40:949-954. 2010
    2010 Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production.  AIDS Research and Human Retroviruses.  26:279-291. 2010
    2009 Tetherin-Driven Adaptation of Vpu and Nef Function and the Evolution of Pandemic and Nonpandemic HIV-1 Strains.  Cell Host and Microbe.  6:409-421. 2009
    2009 P04-12. Characterization of leukopak PBMC phenotypes and biotypes for optimal performance in HIV-1 neutralization assays.  Retrovirology.  6. 2009
    2009 P04-23. HIV-1 neutralization is impacted by the PBMC donor used for both virus growth and target cells, and the effects are neutralization reagent-specific.  Retrovirology.  6. 2009
    2009 P05-04. Neutralizing antibodies induced by immunization with liposomal gp41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes.  Retrovirology.  6. 2009
    2009 P20-15. Evaluation of HIV-1 subtype B acute envelope-expressing infectious molecular clones.  Retrovirology.  6. 2009
    2009 S01-04 OA. Phenotypic analyses of CD8+ T cells that mediate virus inhibition from HIV-1 vaccinees and HIV-1+ virus controllers.  Retrovirology.  6. 2009
    2009 New virologic reagents for neutralizing antibody assays.  Current Opinion in HIV and AIDS.  4:418-425. 2009
    2009 Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection.  Journal of Experimental Medicine.  206:1273-1289. 2009
    2009 Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes..  AIDS.  23:2069-2077. 2009
    2006 T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication.  BioTechniques.  40:91-100. 2006
    2005 Intestinal macrophages: Unique effector cells of the innate immune system.  Immunological Reviews.  206:149-159. 2005
    2005 WNT1 and WNT3a promote expansion of melanocytes through distinct modes of action.  Pigment Cell Research.  18:167-180. 2005
    2002 Novel monoclonal antibody directed at the receptor binding site on the avian sarcoma and leukosis virus Env complex.  Journal of Virology.  76:7518-7527. 2002
    2001 Palmitoylation of the Rous sarcoma virus transmembrane glycoprotein is required for protein stability and virus infectivity.  Journal of Virology.  75:11544-11554. 2001
    2000 The Rous sarcoma virus Env glycoprotein contains a highly conserved motif homologous to tyrosine-based endocytosis signals and displays an unusual internalization phenotype.  Molecular and Cellular Biology.  20:249-260. 2000
    1997 Complement activation by HIV-1-infected cells: The role of transmembrane glycoprotein gp41.  Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology.  14:102-109. 1997
    1997 Analysis of vif-defective human immunodeficiency virus type 1 (HIV-1) virions synthesized in 'non-permissive' T lymphoid cells stably infected with selectable HIV-1.  Journal of General Virology.  78:627-635. 1997
    1996 Unimpaired function of a naturally occurring C terminally truncated vif gene product of human immunodeficiency virus type 1.  Journal of General Virology.  77:1389-1395. 1996
    1995 Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120.  Nature.  375:497-500. 1995
    1993 Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase.  Virology.  192:605-617. 1993

    Research Overview

  • My research focuses on HIV-1 as it relates to mucosal transmission and vaccine development. Much of my work since 2006 occurs in the context of large international consortia (CHAVI, CAVD, IAVI) aimed at HIV-1 vaccine discovery. My goal is:
    (i) To elucidate characteristics of transmitted (‘founder’) HIV-1 infection in vitro, ex vivo of mucosal tissue cells and explants as a surrogate of HIV-1 mucosal transmission, and, recently, in an in vivo mouse as well as non-human primate model.
    (ii) To augment vaccine discovery efforts by developing broadly applicable virologic technology and biologically relevant assay systems that underpin novel immune monitoring assays and facilitates transmission related studies.

    • Principal Investigator On

    Investigator On

    Teaching Overview

  • Full Graduate Faculty, UAB Graduate School

    • Education And Training

  • University of Alabama at Birmingham Department of Microbiology, Postdoctoral Research 2001
  • German Cancer Research Center (DKFZ) Department of Applied Tumorvirology (ATV), Postdoctoral Research 1996
  • Doctor of Science in Virology, Heidelberg University 1996

    • Full Name

  • Christina Ochsenbauer